Adverse reactions were mostly minor, including pain at injection site, fatigue, muscle discomfort, and headaches
Late-stage clinical trials demonstrated higher immune responses than licensed comparator vaccines for both flu and Covid-19 in adults aged 50 years and older
Moderna plans to present phase three study data at an upcoming medical conference and submit information to a peer-reviewed medical journal
Moderna's combination vaccine for Covid-19 and flu targets both diseases in a single shot
Moderna's combination vaccine for Covid-19 and flu, which targets both diseases in a single shot, has shown promising results in late-stage clinical trials. The phase-three trial demonstrated that the vaccine produced higher immune responses than licensed comparator vaccines for both flu and Covid-19 in adults aged 50 years and older. Moderna's CEO, Stéphane Bancel, believes that combination vaccines can potentially reduce the burden on health systems, offer more convenient vaccination options, and provide stronger protection from seasonal illnesses. The adverse reactions to the combination vaccine were mostly minor and included complaints such as pain at the injection site, fatigue, muscle discomfort, and headaches. Moderna plans to present phase three study data at an upcoming medical conference and submit the information to a peer-reviewed medical journal for further evaluation.
The flu strains targeted in Moderna's trial include H1N1, H3N2, and B/Victoria. However, it is important to note that the World Health Organization recommends trivalent flu vaccines for the 2024-2025 season without protection against the B/Yamagata strain, which was included in Moderna's study but is no longer circulating.
Moderna has a history of success with its Covid-19 vaccine and recently received FDA approval for its respiratory syncytial virus (RSV) vaccine. The company continues to expand its portfolio beyond the Covid-19 vaccine, collaborating with Merck on a cancer vaccine.
It is important to note that the World Health Organization recommends trivalent flu vaccines for the 2024-2025 season without protection against the B/Yamagata strain, which was included in Moderna's study but is no longer circulating
Moderna's combined flu and Covid vaccine, which targets both diseases in a single shot, has passed the vital part of final-stage scientific checks.
The phase-three trial shows the vaccine arms the body with protective antibodies as effectively as separate flu and Covid shots.
CEO Stephane Bancel hopes the mRNA vaccine could be made widely available in 2026 or possibly even 2025.
Moderna's mRNA-1083 jab produced a higher immune response than licensed comparator vaccines for flu and matched or bettered currently approved flu jabs.
The results are from 8,000 volunteers all aged over 50 and half over 64.
Accuracy
Fewer injections would be more convenient and simpler according to Moderna.
Moderna plans to file for regulatory approval for its combination jab in the US this summer and hopes it can enter the market in 2025.
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
No overt logical fallacies found in the author's statements. However, there are some problematic aspects such as appeals to authority and inflammatory rhetoric present in quotes from Moderna's CEO, Stephane Bancel.
] Stephane Bancel told BBC News he hoped the messenger ribonucleic acid (mRNA) vaccine could be made widely available in 2026 - or perhaps, 2025.
Moderna’s combination vaccine for Covid-19 and flu was more effective than existing standalone shots in a late-stage trial.
, Moderna plans to file for regulatory approval for its combination jab in the US this summer and hopes it can enter the market in 2025.
, Combination shots could simplify protection against respiratory viruses and reduce burden on healthcare system.
, mRNA-1083, Moderna’s combination shot, produced statistically significantly higher immune responses against three influenza strains and Covid omicron variant XBB.1.5 in both age groups.
, The safety of Moderna’s combination shot was acceptable with common side effects being injection site pain, fatigue, muscle pain and headache.
, Moderna is also developing a combination shot targeting flu, RSV and another vaccine for all three respiratory viruses: Covid, flu and RSV.
Moderna’s combination vaccine, mRNA-1083, targets both COVID-19 and flu.
, Moderna’s combination vaccine had mostly minor adverse reactions such as pain at the injection site, fatigue, muscle discomfort, and headaches.
, Moderna is planning to present phase three study data at an upcoming medical conference and submit the information to a peer-reviewed medical journal.
, Moderna’s CEO, Stéphane Bancel, believes that combination vaccines can potentially reduce the burden on health systems, offer more convenient vaccination options, and provide stronger protection from seasonal illnesses.
, The combination vaccine also showed a sufficient immune response to the B/Yamagata strain of influenza; however, this strain is no longer circulating and the World Health Organization recommends trivalent flu vaccines for the 2024-2025 season without protection against that strain.
, Last month, the FDA approved Moderna’s respiratory syncytial virus (RSV) vaccine, their second approved product after the COVID-19 vaccine.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(50%)
The article is deceptive in the way it presents the results of Moderna's combination vaccine trial. It implies that the study shows definitive and conclusive results, when in fact it only reports 'favorable results'. The author also does not disclose that these are still late-stage clinical trials, which often have uncertainties and variations in outcomes. Furthermore, the article references a press release from Moderna without indicating that the information has not been peer-reviewed or subject to independent scrutiny.
Moderna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune response in late-stage study results than two comparable vaccines on the market.
The company's investigational vaccine, mRNA-1083, combines a vaccine candidate for seasonal influenza and an updated COVID-19 vaccine. Both vaccines have been independently tested and yielded positive results in late-stage clinical trials, according to Moderna,
